Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer

Inclusion Criteria: * Patients with radically resected adenocarcinoma of the stomach and/or gastroesophageal junction with histologic proof of adenocarcinoma, pathologically staged T2-3, any N, M0 * No prior radiation therapy to the stomach or immunotherapy or chemotherapy for any reason * Patients must have a life expectancy of at least 16 weeks and a performance status of \< 2 ECOG scale * Previous adjuvant chemotherapy with Irinotecan, Oxaliplatin and/or 5-FU based regimen. Patients who relapse within the first 6 months after the completion of adjuvant treatment are not eligible for the study. * Patients must have adequate bone marrow function (defined as peripheral absolute granulocyte count of \> 2.000/µL, and platelet count of \> 100.000/µL), adequate liver function (bilirubin \< 1,5 mg/dl), and adequate renal function (creatinine \< 1,5 mg/dl * Patients must be able to understand the nature of this study and give written informed consent Exclusion Criteria: * Patients with T1N0 carcinoma * Positive cytology of pleural, or pericardial effusion or patients with any peritoneal disease diagnosed intra-operatively) * Biopsy proof of lymph node metastases outside the study field such as supraclavicular, mediastinal, or para-aortic nodes * Evidence of metastatic disease to distant organs * Patients with cardiac disease graded as New York Heart Association Class III or IV, severe uncontrolled diabetes, hypertension, cerebron-vascular disease, or infection * Patients with diabetic neuropathy * Abnormalities of mental status such that either the patient cannot fully comprehend the therapeutic implications of the protocol or comply with the requirements * Presence of concurrent or previous malignancies in the past 5 years (except for resected squamous or basal cell carcinoma of the skin) * Pregnant women are excluded from study entry due to the teratogenic effects of the study treatment